Pamplona

• Study of pembrolizumab, lenvatinib and chemotherapy combination in first line lung cancer Ended recruitment
  2024-511412-25-00 4 2022-11-07 First line treatment for extensive-stage small cell lung cancer small
• This study is to find out about the Safety and Efficacy of Epcoritamab in Combination with Rituximab and Lenalidomide (R2) compared to R2 in … Ended recruitment
  2023-505628-67-00 5 2022-10-28 Relapsed and Refractory Follicular Lymphoma
• A Study to Evaluate the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen-Exposed Patients with Relapsed/Refractory Multi … Ended recruitment
  2023-505865-94-00 9 2022-10-26 Relapsed/Refractory Multiple Myeloma
• A research study to see how well CagriSema helps people with excess body weight lose weight Ended recruitment
  2023-506929-11-00 5 2022-10-17 Overweight and obesity
• Extended VRD plus Early Rescue vs Isatuximab-VRD vs Isatuximab-VIberdomide-D for NDMM patients who are candidates for ASCT Ended recruitment
  2024-517008-12-00 5 2022-10-14 Newly-diagnosed multiple myeloma (NDMM)
• A Phase 3 Randomized Study Comparing Talquetamab SC in Combination With Daratumumab SC and Pomalidomide (Tal-DP) or Talquetamab SC in Combin … Ended recruitment
  2023-503467-41-00 5 2022-10-12 Relapsed or Refractory Multiple Myeloma
• A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti- … Ended recruitment
  2023-506871-88-00 3 2022-10-07 Relapsed/Refractory Multiple Myeloma
• Multicenter, phase II, national and open-label study to evaluate Iberdomide-dexamethasone alone or in combination with standard MM treatment … Ended recruitment
  2024-518870-15-00 4 2022-10-03 Multiple Myeloma
• A Phase 1b Study of Bleximenib in Combination with AML Directed Therapies for Participants with Acute Myeloid Leukemia Harboring KMT2A or NP … Ended recruitment
  2023-506582-58-00 3 2022-07-21 Acute Myeloid Leukemia
• Study of efficacy, safety and tolerability of ianalumab versus placebo, in combination with SoC therapy, in participants with active lupus n … Ended recruitment
  2023-508559-37-00 5 2022-07-14 Lupus nephritis
• A study to investigate the efficacy and safety of depemokimab compared with mepolizumab in adults with relapsing or refractory Eosinophilic … Ended recruitment
  2023-510019-20-00 5 2022-07-13 Relapsing or refractory Eosinophilic Granulomatosis with Polyangiitis
• A Phase 1b Study of Bispecific T Cell Redirection Antibodies in Combination with Checkpoint Inhibition for the Treatment of Participants wit … Ended recruitment
  2022-502681-24-00 3 2022-06-22 Relapsed or Refractory Multiple Myeloma
• A clinical study that compares a treatment with Iberdomide, Daratumumab and Dexamethasone against a treatment with Daratumumab, Bortezomib, … Ended recruitment
  2024-510800-35-00 5 2022-06-17 Relapsed or Refractory Multiple Myeloma (RRMM)
• A Study of the Pharmacokinetics, Safety, and Efficacy of ASTX727 in Combination with Venetoclax in AML Ended recruitment
  2024-516294-78-00 4 2022-06-17 Acute Myeloid Leukemia (AML)
• A Study to Evaluate Long-Term Safety and Tolerability of the Port Delivery System with Ranibizumab in Patients with Neovascular Age-Related … Ended recruitment
  2023-507131-38-00 5 2022-05-16 Neovascular Age-Related Macular Degeneration (nAMD)
• Genetic vaccine for the treatment of microsatellite unstable solid tumors Ended recruitment
  2024-514723-42-00 9 2022-05-05 Locally advanced unresectable or metastatic, microsatellite instabilit
• A Phase 2, Multicohort Study of Daratumumab-Based Therapies in Participants with Amyloid Light Chain (AL) Amyloidosis Ended recruitment
  2023-507069-25-00 4 2022-04-29 Amyloid Light Chain Amyloidosis
• A Phase 3 Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant Ended recruitment
  2023-508897-27-00 5 2022-04-28 Multiple Myeloma
• DISCUS: A Randomised Phase II Study Comparing 3 vs 6 Cycles of Platinum-based Chemotherapy Prior to Maintenance Avelumab in Advanced Urothel … Ended recruitment
  2024-518244-20-01 4 2022-04-25 Urothelial Carcinoma
• Phase 3 study of pembrolizumab vs chemotherapy in dMMR advanced or recurrent endometrial carcinoma Ended recruitment
  2023-506361-56-00 5 2022-04-01 Endometrial cancer
• Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer Ended recruitment
  2023-506771-10-00 5 2022-03-11 Breast Neoplasm, Neoplasm Metastasis
• Assessment of effectiveness and safety of luspatercept in patients suffering from lower-risk myelodysplastic syndrome. Ended recruitment
  2024-515069-33-00 5 2022-02-15 Patients with anemia due to IPSS-R defined very low-, low-, or interme
• An Open-Label Extension and Safety Monitoring Study of Acoramidis(AG10) in Participants with Symptomatic Transthyretin Amyloid Cardiomyopath … Ended recruitment
  2024-515092-36-00 5 2022-02-14 Symptomatic Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
• Clinical trial to compare selinexor pomalidomide dexamethasone combination with elotuzumab pomalidomide dexamethasone in multiple myeloma pa … Ended recruitment
  2024-518304-53-00 5 2022-02-02 Relapsed or Refractory Multiple Myeloma (RRMM)

Showing 505–528 of 821 trials